GLENMARK PHARMACEUTICALS LTD.

Glenmark Therapeutics Inc., USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs. This product is comparable to Differin® Gel, 0.1%. The U.S. OTC Adapalene Gel market achieved approximately $45.8 million in sales for the 52-week period ending September 5, 2026. The new pump packaging aims to enhance consumer convenience and strengthen Glenmark's dermatology portfolio in the U.S. The company is committed to providing high-quality, affordable healthcare solutions.

Glenmark Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with the Prohibition of Insider Trading Regulations, 2015, and the company's internal code of conduct. The trading window will be shut for designated persons, including directors, key managerial personnel, identified employees, and their immediate relatives, as well as connected persons. The closure commences from October 01, 2026, and will remain in effect until the declaration of the unaudited financial results (standalone and consolidated) for the second quarter ended September 30, 2026, plus forty-eight hours thereafter. The specific date for the board meeting to approve these results will be communicated separately.

Glenmark Pharmaceuticals Ltd. has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India. The facility has been classified with a Voluntary Action Indicated (VAI) status. The inspection took place from June 22, 2026, to June 30, 2026. This classification suggests that while the FDA noted some observations, they do not currently warrant mandatory regulatory action, indicating a generally satisfactory inspection outcome for the facility.

Glenmark Pharmaceuticals Ltd. announced the launch of its RYALTRIS® Nasal Spray in Brazil through its subsidiary, Glenmark Specialty S.A. This launch follows regulatory approval from ANVISA and introduces a dual-action therapy for allergic rhinitis, combining olopatadine and mometasone furoate. Brazil represents a significant market in Latin America, with an estimated 20-30% of its population affected by allergic rhinitis. RYALTRIS® is Glenmark's first globally commercialized innovative product and is now approved in 57 markets worldwide.

Glenmark Pharmaceuticals Inc., USA has announced the launch of Calcium Gluconate Injection USP in multiple dosage forms: 1,000 mg/10 mL, 5,000 mg/50 mL Single-Dose Vials, and 10,000 mg/100 mL Pharmacy Bulk Package. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi USA's Calcium Gluconate Injection. The U.S. market for this injection achieved approximately $69.9 million in sales for the 12 months ending June 2026, according to IQVIA data. This launch strengthens Glenmark's U.S. injectables business and hospital portfolio, aligning with their strategy to build a differentiated and sustainable injectables business.

Glenmark Pharmaceuticals Limited has received U.S. FDA approval for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. This product is bioequivalent and therapeutically equivalent to Flonase® Nasal Spray, 0.05 mg/spray, a reference drug by Haleon US Holdings LLC. The nasal spray will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The market for Flonase® Nasal Spray achieved approximately $295.2 million in annual sales for the 12 months ending June 2026, according to IQVIA® sales data. This approval signifies an expansion of Glenmark's respiratory portfolio in the U.S., aiming to provide affordable treatment options.

Glenmark Pharmaceuticals Ltd is sending letters to shareholders whose email addresses are not registered, providing a web link and QR code to access the Integrated Annual Report and AGM Notice for FY 2025-26. This communication is in compliance with SEBI Listing Regulations. The 48th Annual General Meeting is scheduled for September 11, 2026, to be held via Video Conference. Shareholders can opt for permanent email registration for future communications.

Glenmark Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Reporting (BRSR) for the Financial Year 2025-26, as per SEBI regulations. The report details the company's corporate identity, registered and corporate addresses, and contact information for queries. It outlines the company's business activities, primarily focused on pharmaceuticals, encompassing research & development, manufacturing, and sales of generics, specialty medications, and OTC treatments across various therapeutic areas. The reporting boundary is standalone unless otherwise stated. The company operates 8 plants and 19 offices nationally, and 3 plants and 48 offices internationally, serving 28 states and 8 union territories in India and over 80 countries globally. Exports contributed 57.99% of the total standalone turnover.

Glenmark Pharmaceuticals Limited has announced its 48th Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 2:00 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with MCA and SEBI regulations. The company has also released its Integrated Annual Report, including BRSR for the Financial Year 2025-26, which is available on the company's website and NSDL's e-voting portal. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, declaration of a dividend of INR 2.50 per equity share, re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director, and ratification of the Cost Auditor's remuneration for FY27.

Glenmark Pharmaceuticals Limited has announced its 48th Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 2:00 p.m. IST via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The meeting will cover ordinary business including the adoption of audited standalone and consolidated financial statements for the Financial Year ended March 31, 2026, and the declaration of a dividend of INR 2.50 per equity share. Special business includes the re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director and ratification of remuneration for the Cost Auditor, M/s. R A & Co., for the Financial Year ending March 31, 2027. The notice of the AGM is available on the company's website and NSDL's e-voting portal.